SCHEMBL25760663

SCHEMBL25760663

C=C(NC(C)C)C(C)N1CCC(c2ccccc2)C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 4/20 0.43
▸ RAB9A P51151 4/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ TP53 P04637 1/20 0.43
▸ GAA P10253 2/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ PDE9A O76083 2/20 0.42
▸ KCNH2 Q12809 1/20 0.42
▸ HRH3 Q9Y5N1 1/20 0.42
▸ MAPT P10636 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ NFKB1 P19838 1/20 0.40
▸ NFKB2 Q00653 1/20 0.40
▸ RELA Q04206 1/20 0.40
▸ AGTR2 P50052 1/20 0.40
▸ DRD2 P14416 1/20 0.40
▸ DRD1 P21728 1/20 0.40
▸ DRD4 P21917 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25760660 0.87 NPC1 (0.41) NPC1RAB9ASMN1; SMN2TP53GAA
SCHEMBL24450335 0.84 RAB9A (0.49) NPC1RAB9ASMN1; SMN2TP53KCNH2
SCHEMBL24112381 0.77 NPC1 (0.50) NPC1RAB9ASMN1; SMN2TP53GAA
SCHEMBL24450336 0.76 NPC1 (0.47) NPC1RAB9ASMN1; SMN2TP53PDE9A
SCHEMBL12609029 0.76 HRH3 (0.56) KCNH2HRH3DRD2DRD1DRD4
SCHEMBL2603285 0.76 HRH3 (0.56) KCNH2HRH3DRD2DRD1DRD4
SCHEMBL12609017 0.76 HRH3 (0.56) KCNH2HRH3DRD2DRD1DRD4
SCHEMBL25760664 0.76 HTT (0.53) GAAKMT2AALDH1A1DRD2DRD1
SCHEMBL24029313 0.74 OPRM1 (0.47) NPC1RAB9ASMN1; SMN2TP53GAA
SCHEMBL20005705 0.73 RAB9A (0.60) NPC1RAB9ASMN1; SMN2TP53GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-07-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTRL, CTSL, CTSV NPC1 481/4885RAB9A 2344/4885SMN1; SMN2 3613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback